{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:18:47Z","timestamp":1790205527890,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T00:00:00Z","timestamp":1460419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11033-016-3983-1","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T04:12:44Z","timestamp":1460607164000},"page":"473-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Mohammed","family":"Jarrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Behl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganiraju","family":"Manyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Ganah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Nasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"3983_CR1","unstructured":"World Health Organization (2015) Cardiovascular diseases (CVDs) Fact sheet No. 317. Available http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/"},{"issue":"14","key":"3983_CR2","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1517\/14656566.2015.1079619","volume":"16","author":"EL Grove","year":"2015","unstructured":"Grove EL et al (2015) Antiplatelet therapy in acute coronary syndromes. Expert Opin Pharmacother 16(14):2133\u20132147","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"3983_CR3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/MOG.0b013e32834a382e","volume":"27","author":"NS Abraham","year":"2011","unstructured":"Abraham NS (2011) Prescribing proton pump inhibitor and clopidogrel together: current state of recommendations. Curr Opin Gastroenterol 27(6):558\u2013564","journal-title":"Curr Opin Gastroenterol"},{"issue":"5","key":"3983_CR4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","volume":"110","author":"EM Antman","year":"2004","unstructured":"Antman EM et al (2004) ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction\u2014executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110(5):588\u2013636","journal-title":"Circulation"},{"issue":"16","key":"3983_CR5","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354(16):1706\u20131717","journal-title":"N Engl J Med"},{"key":"3983_CR6","unstructured":"George MG et al (2012) Recommended use of aspirin and other antiplatelet medications among adults\u2014National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005\u20132008. MMWR Morb Mortal Wkly Rep, vol 61(1)"},{"key":"3983_CR7","unstructured":"Gu Q et al (2014) Preventive aspirin and other antiplatelet medication use among US adults aged \u226540 years: data from the National Health and Nutrition Examination Survey, 2011\u20132012. Public health reports (Washington, DC: 1974), vol 130(6), pp 643\u2013654"},{"issue":"4","key":"3983_CR8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.amjcard.2009.10.014","volume":"105","author":"CP Cannon","year":"2010","unstructured":"Cannon CP et al (2010) Current use of aspirin and antithrombotic agents in the united states among outpatients with atherothrombotic disease (from the reduction of atherothrombosis for continued health [REACH] registry). Am J Cardiol 105(4):445\u2013452","journal-title":"Am J Cardiol"},{"issue":"24","key":"3983_CR9","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","volume":"122","author":"NS Abraham","year":"2010","unstructured":"Abraham NS et al (2010) ACCF\/ACG\/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 122(24):2619\u20132633","journal-title":"Circulation"},{"issue":"7","key":"3983_CR10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494\u2013502","journal-title":"N Engl J Med"},{"issue":"7422","key":"3983_CR11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature11632","volume":"491","author":"Genomes Project Consortium","year":"2012","unstructured":"Genomes Project Consortium (2012) An integrated map of genetic variation from 1092 human genomes. Nature 491(7422):56\u201365","journal-title":"Nature"},{"issue":"2","key":"3983_CR12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-0038-1648859","volume":"72","author":"P Savi","year":"1994","unstructured":"Savi P et al (1994) The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72(2):313\u2013317","journal-title":"Thromb Haemost"},{"issue":"1","key":"3983_CR13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","volume":"38","author":"M Kazui","year":"2010","unstructured":"Kazui M et al (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38(1):92\u201399","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"3983_CR14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","volume":"84","author":"P Savi","year":"2000","unstructured":"Savi P et al (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84(5):891\u2013896","journal-title":"Thromb Haemost"},{"issue":"12","key":"3983_CR15","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1161\/STROKEAHA.110.594069","volume":"41","author":"CD Anderson","year":"2010","unstructured":"Anderson CD et al (2010) Personalized approaches to clopidogrel therapy: are we there yet? Stroke 41(12):2997\u20133002","journal-title":"Stroke"},{"issue":"4","key":"3983_CR16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","volume":"52","author":"JA Goldstein","year":"2001","unstructured":"Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52(4):349\u2013355","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3983_CR17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003088-199529030-00005","volume":"29","author":"L Bertilsson","year":"1995","unstructured":"Bertilsson L (1995) Geographical\/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29(3):192\u2013209","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"3983_CR18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10654-007-9196-0","volume":"22","author":"Y Ghodke","year":"2007","unstructured":"Ghodke Y et al (2007) Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol 22(12):907\u2013915","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"3983_CR19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FPC.0b013e328363688d","volume":"23","author":"EW Chua","year":"2013","unstructured":"Chua EW et al (2013) Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine. Pharmacogenet Genom 23(9):494\u2013497","journal-title":"Pharmacogenet Genom"},{"issue":"3","key":"3983_CR20","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s11033-010-0282-0","volume":"38","author":"B Jin","year":"2011","unstructured":"Jin B et al (2011) Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep 38(3):1697\u20131702","journal-title":"Mol Biol Rep"},{"issue":"12","key":"3983_CR21","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","volume":"41","author":"Z Desta","year":"2002","unstructured":"Desta Z et al (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41(12):913\u2013958","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3983_CR22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103\u2013113","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3983_CR23","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2125.2012.04328.x","volume":"74","author":"RR Shah","year":"2012","unstructured":"Shah RR, Shah DR (2012) Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol 74(4):698\u2013721","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3983_CR24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00228-012-1381-8","volume":"69","author":"K Subraja","year":"2013","unstructured":"Subraja K et al (2013) Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Eur J Clin Pharmacol 69(3):415\u2013422","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3983_CR25","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0022-3565(24)37748-1","volume":"286","author":"GC Ibeanu","year":"1998","unstructured":"Ibeanu GC et al (1998) Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286(3):1490\u20131495","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"3983_CR26","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0169-409X(02)00076-5","volume":"54","author":"HG Xie","year":"2002","unstructured":"Xie HG et al (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54(10):1257\u20131270","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"3983_CR27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","volume":"34","author":"S Rendic","year":"2002","unstructured":"Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34(1\u20132):83\u2013448","journal-title":"Drug Metab Rev"},{"issue":"7","key":"3983_CR28","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.105.003822","volume":"33","author":"JN Roy","year":"2005","unstructured":"Roy JN et al (2005) CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 33(7):884\u2013887","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3983_CR29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0006-2952(87)90350-9","volume":"36","author":"M Kitada","year":"1987","unstructured":"Kitada M et al (1987) Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations. Biochem Pharmacol 36(4):453\u2013456","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"3983_CR30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/0003-9861(88)90655-8","volume":"263","author":"DJ Waxman","year":"1988","unstructured":"Waxman DJ et al (1988) Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 263(2):424\u2013436","journal-title":"Arch Biochem Biophys"},{"key":"3983_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2350-6-19","volume":"6","author":"AA Garsa","year":"2005","unstructured":"Garsa AA, McLeod HL, Marsh S (2005) CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 6:19","journal-title":"BMC Med Genet"},{"issue":"8","key":"3983_CR32","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.TP.0000090753.99170.89","volume":"76","author":"E Thervet","year":"2003","unstructured":"Thervet E et al (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76(8):1233\u20131235","journal-title":"Transplantation"},{"issue":"2","key":"3983_CR33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0041-008X(02)00028-5","volume":"186","author":"YM Zheng","year":"2003","unstructured":"Zheng YM et al (2003) Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicol Appl Pharmacol 186(2):119\u2013126","journal-title":"Toxicol Appl Pharmacol"},{"issue":"12","key":"3983_CR34","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.healun.2011.08.001","volume":"30","author":"V Gijsen","year":"2011","unstructured":"Gijsen V et al (2011) Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transpl 30(12):1352\u20131359","journal-title":"J Heart Lung Transpl"},{"issue":"18","key":"3983_CR35","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/heartjnl-2012-301892","volume":"98","author":"KW Park","year":"2012","unstructured":"Park KW et al (2012) Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart 98(18):1366\u20131372","journal-title":"Heart"},{"issue":"11","key":"3983_CR36","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1007\/s11033-014-3613-8","volume":"41","author":"R Priyadharsini","year":"2014","unstructured":"Priyadharsini R et al (2014) Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population. Mol Biol Rep 41(11):7265\u20137271","journal-title":"Mol Biol Rep"},{"issue":"12","key":"3983_CR37","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1503\/cmaj.060664","volume":"174","author":"JW Suh","year":"2006","unstructured":"Suh JW et al (2006) Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174(12):1715\u20131722","journal-title":"CMAJ"},{"issue":"6","key":"3983_CR38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00228-008-0471-0","volume":"64","author":"KA Kim","year":"2008","unstructured":"Kim KA, Park PW, Park JY (2008) Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 64(6):589\u2013597","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3983_CR39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ehj.2011.08.025","volume":"63","author":"AA Saad","year":"2011","unstructured":"Saad AA et al (2011) Effect of cytochrome P450 3A5 polymorphism on platelet reactivity after treatment with clopidogrel in patients scheduled for percutaneous coronary intervention. Egypt Heart J 63(1):23\u201331","journal-title":"Egypt Heart J"},{"issue":"10","key":"3983_CR40","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1021\/ml3002067","volume":"3","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Zhou J (2012) Identification of the significant involvement and mechanistic role of CYP3A4\/5 in clopidogrel bioactivation. ACS Med Chem Lett 3(10):844\u2013849","journal-title":"ACS Med Chem Lett"},{"issue":"Suppl 2","key":"3983_CR41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","volume":"23","author":"G Sachs","year":"2006","unstructured":"Sachs G, Shin JM, Howden CW (2006) Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23(Suppl 2):2\u20138","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"3983_CR42","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3748\/wjg.v18.i18.2161","volume":"18","author":"MD Drepper","year":"2012","unstructured":"Drepper MD, Spahr L, Frossard JL (2012) Clopidogrel and proton pump inhibitors: where do we stand in 2012? World J Gastroenterol 18(18):2161\u20132171","journal-title":"World J Gastroenterol"},{"issue":"6","key":"3983_CR43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejim.2010.08.004","volume":"21","author":"M Lettino","year":"2010","unstructured":"Lettino M (2010) Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies? Eur J Intern Med 21(6):484\u2013489","journal-title":"Eur J Intern Med"},{"issue":"18","key":"3983_CR44","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1093\/eurheartj\/ehp256","volume":"30","author":"GV Moukarbel","year":"2009","unstructured":"Moukarbel GV et al (2009) Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 30(18):2226\u20132232","journal-title":"Eur Heart J"},{"issue":"2","key":"3983_CR45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11606-012-2208-0","volume":"28","author":"EL Grove","year":"2013","unstructured":"Grove EL et al (2013) Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. J Gen Intern Med 28(2):216\u2013222","journal-title":"J Gen Intern Med"},{"issue":"2","key":"3983_CR46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3949\/ccjm.77a.09173","volume":"77","author":"JP Depta","year":"2010","unstructured":"Depta JP, Bhatt DL (2010) Omeprazole and clopidogrel: should clinicians be worried? Clevel Clin J Med 77(2):113\u2013116","journal-title":"Clevel Clin J Med"},{"issue":"20","key":"3983_CR47","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL et al (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363(20):1909\u20131917","journal-title":"N Engl J Med"},{"issue":"7","key":"3983_CR48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","volume":"180","author":"DN Juurlink","year":"2009","unstructured":"Juurlink DN et al (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 180(7):713\u2013718","journal-title":"Can Med Assoc J"},{"issue":"5","key":"3983_CR49","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2174\/157016111205140926161509","volume":"12","author":"J Juel","year":"2014","unstructured":"Juel J, Pareek M, Jensen SE (2014) The clopidogrel-PPI interaction: an updated mini-review. Curr Vasc Pharmacol 12(5):751\u2013757","journal-title":"Curr Vasc Pharmacol"},{"issue":"4","key":"3983_CR50","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jcin.2010.12.009","volume":"4","author":"US Tantry","year":"2011","unstructured":"Tantry US, Kereiakes DJ, Gurbel PA (2011) Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 4(4):365\u2013380","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"3983_CR51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","volume":"51","author":"M Gilard","year":"2008","unstructured":"Gilard M et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51(3):256\u2013260","journal-title":"J Am Coll Cardiol"},{"issue":"9660","key":"3983_CR52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","volume":"373","author":"JP Collet","year":"2009","unstructured":"Collet JP et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660):309\u2013317","journal-title":"Lancet"},{"issue":"4","key":"3983_CR53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon T et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360(4):363\u2013375","journal-title":"N Engl J Med"},{"issue":"12","key":"3983_CR54","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01213011-200512000-00003","volume":"15","author":"I Ieiri","year":"2005","unstructured":"Ieiri I et al (2005) Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. Pharmacogenet Genom 15(12):851\u2013859","journal-title":"Pharmacogenet Genom"},{"issue":"5","key":"3983_CR55","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/bdd.1795","volume":"33","author":"CH Chen","year":"2012","unstructured":"Chen CH et al (2012) Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos 33(5):278\u2013283","journal-title":"Biopharm Drug Dispos"},{"issue":"23","key":"3983_CR56","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","volume":"34","author":"S Agewall","year":"2013","unstructured":"Agewall S et al (2013) Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 34(23):1708\u20131713","journal-title":"Eur Heart J"},{"issue":"5","key":"3983_CR57","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","volume":"96","author":"M W\u00fcrtz","year":"2010","unstructured":"W\u00fcrtz M et al (2010) The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 96(5):368\u2013371","journal-title":"Heart"},{"key":"3983_CR58","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","volume":"342","author":"M Charlot","year":"2011","unstructured":"Charlot M et al (2011) Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 342:d2690","journal-title":"BMJ"},{"issue":"11","key":"3983_CR59","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/ajg.2010.334","volume":"105","author":"OS Boxel van","year":"2010","unstructured":"van Boxel OS et al (2010) Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 105(11):2430\u20132436","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"3983_CR60","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","volume":"103","author":"B Giusti","year":"2009","unstructured":"Giusti B et al (2009) Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 103(6):806\u2013811","journal-title":"Am J Cardiol"},{"issue":"24","key":"3983_CR61","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehq321","volume":"31","author":"AM Harmsze","year":"2010","unstructured":"Harmsze AM et al (2010) CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 31(24):3046\u20133053","journal-title":"Eur Heart J"},{"issue":"10","key":"3983_CR62","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/j.1538-7836.2011.04483.x","volume":"9","author":"AM Harmsze","year":"2011","unstructured":"Harmsze AM et al (2011) Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost 9(10):1892\u20131901","journal-title":"J Thromb Haemost"},{"issue":"7","key":"3983_CR63","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1253\/circj.72.1165","volume":"72","author":"LA Malek","year":"2008","unstructured":"Malek LA et al (2008) Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 72(7):1165\u20131169","journal-title":"Circ J"},{"issue":"2","key":"3983_CR64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/hrt.2011.227272","volume":"98","author":"I-Y Oh","year":"2012","unstructured":"Oh I-Y et al (2012) Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 98(2):139\u2013144","journal-title":"Heart"},{"issue":"6","key":"3983_CR65","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/j.thromres.2011.07.028","volume":"128","author":"T Ono","year":"2011","unstructured":"Ono T et al (2011) Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thromb Res 128(6):e130\u2013e136","journal-title":"Thromb Res"},{"issue":"1","key":"3983_CR66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1253\/circj.CJ-10-0525","volume":"75","author":"T Sawada","year":"2011","unstructured":"Sawada T et al (2011) Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 75(1):99\u2013105","journal-title":"Circ J"},{"issue":"8","key":"3983_CR67","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8):849\u2013857","journal-title":"JAMA"},{"issue":"8","key":"3983_CR68","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","volume":"30","author":"D Sibbing","year":"2009","unstructured":"Sibbing D et al (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30(8):916\u2013922","journal-title":"Eur Heart J"},{"issue":"4","key":"3983_CR69","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","volume":"121","author":"D Sibbing","year":"2010","unstructured":"Sibbing D et al (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4):512\u2013518","journal-title":"Circulation"},{"issue":"13","key":"3983_CR70","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","volume":"32","author":"D Sibbing","year":"2011","unstructured":"Sibbing D et al (2011) No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 32(13):1605\u20131613","journal-title":"Eur Heart J"},{"issue":"20","key":"3983_CR71","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","volume":"51","author":"D Trenk","year":"2008","unstructured":"Trenk D et al (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51(20):1925\u20131934","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3983_CR72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000329048","volume":"119","author":"SD Yan","year":"2011","unstructured":"Yan SD et al (2011) The value of combining CYP2C19*2 polymorphism with classic risk factors in prediction of clinical prognosis in acute coronary syndrome patients. Cardiology 119(1):15\u201320","journal-title":"Cardiology"},{"issue":"4","key":"3983_CR73","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354\u2013362","journal-title":"N Engl J Med"},{"issue":"9749","key":"3983_CR74","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L et al (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749):1320\u20131328","journal-title":"Lancet"},{"issue":"1","key":"3983_CR75","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","volume":"17","author":"HJ Bouman","year":"2011","unstructured":"Bouman HJ et al (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17(1):110\u2013116","journal-title":"Nat Med"},{"issue":"3","key":"3983_CR76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.recesp.2011.07.013","volume":"65","author":"A Tello-Montoliu","year":"2012","unstructured":"Tello-Montoliu A et al (2012) Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev Esp Cardiol 65(3):219\u2013226 Engl Ed","journal-title":"Rev Esp Cardiol"},{"issue":"18","key":"3983_CR77","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","volume":"363","author":"G Pare","year":"2010","unstructured":"Pare G et al (2010) Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363(18):1704\u20131714","journal-title":"N Engl J Med"},{"issue":"3","key":"3983_CR78","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/clpt.2008.215","volume":"85","author":"YS Kang","year":"2009","unstructured":"Kang YS et al (2009) The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 85(3):312\u2013318","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"3983_CR79","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/aje\/kwh294","volume":"160","author":"C Keshava","year":"2004","unstructured":"Keshava C, McCanlies EC, Weston A (2004) CYP3A4 polymorphisms: potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 160(9):825\u2013841","journal-title":"Am J Epidemiol"},{"issue":"3","key":"3983_CR80","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0090-9556(24)15374-3","volume":"28","author":"RW Wang","year":"2000","unstructured":"Wang RW et al (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28(3):360\u2013366","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3983_CR81","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0022-3565(24)29199-0","volume":"299","author":"D Dai","year":"2001","unstructured":"Dai D et al (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299(3):825\u2013831","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"3983_CR82","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1081\/DMR-200028805","volume":"37","author":"B Chowbay","year":"2005","unstructured":"Chowbay B, Zhou S, Lee EJ (2005) An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 37(2):327\u2013378","journal-title":"Drug Metab Rev"},{"issue":"1","key":"3983_CR83","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2005.07.106","volume":"97","author":"DJ Angiolillo","year":"2006","unstructured":"Angiolillo DJ et al (2006) Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 97(1):38\u201343","journal-title":"Am J Cardiol"},{"issue":"2","key":"3983_CR84","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","volume":"109","author":"WC Lau","year":"2004","unstructured":"Lau WC et al (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109(2):166\u2013171","journal-title":"Circulation"},{"issue":"12","key":"3983_CR85","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","volume":"17","author":"B Giusti","year":"2007","unstructured":"Giusti B et al (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+ 12G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genom 17(12):1057\u20131064","journal-title":"Pharmacogenet Genom"},{"issue":"10","key":"3983_CR86","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2007.02722.x","volume":"5","author":"P Fontana","year":"2007","unstructured":"Fontana P et al (2007) Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 5(10):2153\u20132155","journal-title":"J Thromb Haemost"},{"key":"3983_CR87","first-page":"S_815","volume":"118","author":"SP Dunn","year":"2008","unstructured":"Dunn SP et al (2008) Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 118:S_815","journal-title":"Circulation"},{"issue":"6","key":"3983_CR88","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7326\/0003-4819-153-6-201009210-00005","volume":"153","author":"M Charlot","year":"2010","unstructured":"Charlot M et al (2010) Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 153(6):378\u2013386","journal-title":"Ann Intern Med"},{"issue":"9","key":"3983_CR89","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","volume":"301","author":"P Ho","year":"2009","unstructured":"Ho P et al (2009) RIsk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9):937\u2013944","journal-title":"JAMA"},{"issue":"6","key":"3983_CR90","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.amjcard.2010.10.073","volume":"107","author":"S Banerjee","year":"2011","unstructured":"Banerjee S et al (2011) Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol 107(6):871\u2013878","journal-title":"Am J Cardiol"},{"issue":"6","key":"3983_CR91","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-152-6-201003160-00003","volume":"152","author":"WA Ray","year":"2010","unstructured":"Ray WA et al (2010) Outcomes with concurrent use of clopidogrel and proton-pump inhibitorsa cohort study. Ann Intern Med 152(6):337\u2013345","journal-title":"Ann Intern Med"},{"issue":"23","key":"3983_CR92","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/CIRCULATIONAHA.109.873497","volume":"120","author":"JA Rassen","year":"2009","unstructured":"Rassen JA et al (2009) Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 120(23):2322\u20132329","journal-title":"Circulation"},{"issue":"5","key":"3983_CR93","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCULATIONAHA.110.965640","volume":"123","author":"T Simon","year":"2011","unstructured":"Simon T et al (2011) Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) registry. Circulation 123(5):474\u2013482","journal-title":"Circulation"},{"issue":"10s1","key":"3983_CR94","doi-asserted-by":"crossref","first-page":"A179.E1675","DOI":"10.1016\/S0735-1097(10)61676-2","volume":"55","author":"KJ Harjai","year":"2010","unstructured":"Harjai KJ et al (2010) Six-month outcomes with or without proton-pump inhibitors after successful PCI: insights from the Guthrie PCI Registry. J Am Coll Cardiol 55(10s1):A179.E1675\u2013A179.E1675","journal-title":"J Am Coll Cardiol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-016-3983-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-016-3983-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-016-3983-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T13:41:41Z","timestamp":1748871701000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-016-3983-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3983"],"URL":"https:\/\/doi.org\/10.1007\/s11033-016-3983-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.31221\/osf.io\/tcbge","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,12]]}}}